I-Semalutide, i-glucagon efana ne-peptide (GLP-1) receptor agonist, igunyazwe ukwelapha uhlobo lwesifo sikashukela sohlobo 2. I-Somaglutide yathuthukiswa nguNovo Nordisk ku-2012 njengenye indlela yesikhathi eside ye-Liraglutide. Uma kuqhathaniswa neLiraglutide neminye imithi yesifo sikashukela, enye yezinzuzo zeSomaglutide ukuthi inesikhathi eside sokusebenza, ngakho-ke umjovo kanye ngesonto kwanele. NgoDisemba 2017, i-US Food and Drug Administration (FDA) yagunyaza uhlobo lomjovo lwe-somalutide. Ukuhlolwa komtholampilo kwesigaba sesibili sesigaba sesibili sathola ukuthi i-Somaglutide inciphisa isisindo sohlobo lwe-2 yesifo sikashukela kanye nabantu abakhuluphele, futhi ukulahlekelwa isisindo kwakubhekwa njengokunciphisa amandla okutholwa okubangelwa ukunciphisa ukudla.